主页文献库搜索
Comparative analysis of microRNA expression in serum and plasma in patients s...

Smyczynska(U),Rycerz(A),Kozlowska(K),Symec... Biomark Res 2026-01-09

...BRCA1/2 pathogenic variants, from three centers were collected. MiRNAs were quantified using miRNA sequencing (miRNA-seq...

Prevalence of Germline Variants in Breast, Ovarian, and Prostate Cancer in Ur...

Alzogaray(V) Clin Genet 2026-06-00

...BRCA1/2 variants accounted for 25% of positive cases, while 61.5% involved non-BRCA genes (ATM, RAD51C, MUTYH). No recur...

Genomic landscape of metastatic breast cancers in young adults: a liquid biop...

Diab(E),Roussel-Simonin(C),Giugliano(F),Di... Breast 2026-02-00

...BRCA1 (22 %), RB1 (17 %). PTEN mutations were more frequent among YA with TNBC than older patients (26 % vs 8 %; p = 0.0...

IFI16 senses and protects stalled replication forks.

Gamble(A),Ward(TA),Wheeler(OPG),Morris(JP)... Mol Cell 2026-01-22

...BRCA1 and BRCA2. IFI16 acts directly at stalled replication forks to protect nascent DNA from degradation by the nucleas...

Functional footprints of homologous recombination deficiency in prostate canc...

Vlachos(G),Moser(T),Lazzeri(I),Moser(MJ),G... Br J Cancer 2026-03-00

...BRCA1/2 mutation testing or genomic scars, fail to capture the full spectrum of HRD. Tissue-based testing is further ham...

The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Mo...

Huz(M),Karadag Soylu(N),Koc(A),Kucukakcali... Diagnostics (Basel) 2026-01-04

...BRCA1) in HBV-HCC and cryptogenic hepatocellular carcinoma (Cr-HCC) cases. Methods: The study groups consisted of HBV-HC...

Precision oncology promise in the management of pancreatic acinar cell carcin...

Baskar(S),Patel(RR),Gao(MT),Rose(BE),Bawek... Eur J Cancer 2026-02-05

...BRCA1/2, ATM), and mismatch repair (MMR) genes, which may have potential therapeutic implications. Targeted therapies ha...

Evaluation of quantitative polymerase chain reaction for detecting BRCA1 or B...

Oswald(AJ),Hollis(RL),Churchman(M),Croy(I)... Sci Rep 2026-01-10

...BRCA1/2 CNL in both clinical cohorts was poor (BRCA1; 0-11.5%, BRCA2; 10-36.8%). There was frequent co-occurrence of BRC...

Evaluating carboplatin and PARP inhibitor combination efficacy using high-gra...

Tomas(EJ),Davis(J),Ramos Valdes(Y),Shepher... Cancer Biol Ther 2026-12-31

...BRCA1/2-mutated HGSC, and niraparib is approved for platinum-sensitive recurrent disease. However, research is currently...

Leveraging tumor multigene panel testing to identify germline variants in gyn...

Parulekar(M),Kim(YN),Kim(K),Lee(S),No(JH),... Gynecol Oncol 2026-02-00

...BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, BRIP1, RAD51C, RAD51D, ATM, and CHEK2) with a variant allele frequency (VAF) of ≥...

上一页 79 80 81 82 83 84 85 86 87 下一页 83 / 共 1000

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com